[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size study, by Type (Intravenous, Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecasts 2022-2032

July 2024 | 200 pages | ID: GBE89DABBEF3EN
Bizwit Research & Consulting LLP

US$ 4,950.00

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market is valued approximately at USD 788.91 million in 2023 and is anticipated to grow with a healthy growth rate of more than 12.48% over the forecast period 2024-2032. Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. This debilitating condition leads to the degeneration of voluntary muscles, resulting in loss of motor function and eventual respiratory failure. The increasing incidence of ALS, unmet treatment needs, and rising research funding for neurodegenerative disease therapeutics are key drivers propelling the market growth. The aging population and the development of novel drugs further contribute to the expansion of the ALS treatment market.

Despite significant advancements, the high cost of treatment and stringent regulatory guidelines pose substantial challenges. However, continuous efforts to develop cost-effective treatments and improve access to affordable therapies are crucial to addressing these challenges. The market is also witnessing opportunities with the advent of novel therapies and increased awareness about ALS.

The key regions considered for the global Amyotrophic Lateral Sclerosis (ALS) Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Amyotrophic Lateral Sclerosis (ALS) Treatment Market in terms of revenue. The market growth in the region is being attributed to factors including high incidence of ALS compared to other regions. Also, advanced healthcare infrastructure: Established healthcare infrastructure allows for early diagnosis, better management of ALS, and access to specialized treatments. The presence of leading pharmaceutical companies and research institutions fuels innovation in ALS treatments, leading to a wider range of options for patients. The presence of leading companies such as Pfizer, Sangamo Therapeutics, and Celgene, along with increased investments in patient awareness initiatives, propels market growth in this region. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by increased public and healthcare professional awareness of ALS leads to earlier diagnosis and a greater need for treatment options. As the population ages in Asia Pacific, the number of people susceptible to ALS naturally increases, creating a larger patient pool. Also, with developing economies in the region, spending on healthcare is rising, making ALS treatments more accessible to patients. Growing recognition of the benefits of early intervention is propelling the market for ALS treatments that can slow disease progression.

Major market players included in this report are:

AB Science SA

Alkem Laboratories Ltd.

Apotex Inc.

Aquestive Therapeutics Inc.

Biogen Inc.

Brainstorm Cell Therapeutics Inc.

CORESTEM Inc.

Cytokinetics Inc.

Dr Reddys Laboratories Ltd.

Eledon Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc.

Italfarmaco Holding SPA

Medindia Health

Mitsubishi Chemical Group Corp.

Otsuka Holdings Co. Ltd.

The detailed segments and sub-segment of the market are explained below:

By Type
  • Intravenous
  • Oral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Region:

North America
  • U.S.
  • Canada
Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
Latin America
  • Brazil
  • Mexico
  • RoLA
Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA
Years considered for the study are as follows:
  • Historical year – 2022
  • Base year – 2023
  • Forecast period – 2024 to 2032
Key Takeaways:
  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.
CHAPTER 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT MARKET EXECUTIVE SUMMARY

1.1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
  1.3.1. By Type
  1.3.2. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT MARKET DEFINITION AND RESEARCH ASSUMPTIONS

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
  2.3.1. Inclusion & Exclusion
  2.3.2. Limitations
  2.3.3. Supply Side Analysis
    2.3.3.1. Availability
    2.3.3.2. Infrastructure
    2.3.3.3. Regulatory Environment
    2.3.3.4. Market Competition
    2.3.3.5. Economic Viability (Consumer’s Perspective)
  2.3.4. Demand Side Analysis
    2.3.4.1. Regulatory frameworks
    2.3.4.2. Technological Advancements
    2.3.4.3. Environmental Considerations
    2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT MARKET DYNAMICS

3.1. Market Drivers
  3.1.1. High research funding
  3.1.2. Increasing aging population
  3.1.3. Rising incidence of ALS
3.2. Market Challenges
  3.2.1. High treatment costs
  3.2.2. Stringent regulatory guidelines
3.3. Market Opportunities
  3.3.1. Development of novel drugs
  3.3.2. Increased awareness about ALS

CHAPTER 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT MARKET INDUSTRY ANALYSIS

4.1. Porter’s 5 Force Model
  4.1.1. Bargaining Power of Suppliers
  4.1.2. Bargaining Power of Buyers
  4.1.3. Threat of New Entrants
  4.1.4. Threat of Substitutes
  4.1.5. Competitive Rivalry
  4.1.6. Futuristic Approach to Porter’s 5 Force Model
  4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
  4.2.1. Political
  4.2.2. Economical
  4.2.3. Social
  4.2.4. Technological
  4.2.5. Environmental
  4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT MARKET SIZE & FORECASTS BY TYPE 2022-2032

5.1. Segment Dashboard
5.2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
  5.2.1. Intravenous
  5.2.2. Oral

CHAPTER 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL 2022-2032

6.1. Segment Dashboard
6.2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million)
  6.2.1. Hospital Pharmacies
  6.2.2. Retail Pharmacies
  6.2.3. Online Pharmacies

CHAPTER 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT MARKET SIZE & FORECASTS BY REGION 2022-2032

7.1. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.1.1. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market
    7.1.1.1. Type breakdown size & forecasts, 2022-2032
    7.1.1.2. Distribution Channel breakdown size & forecasts, 2022-2032
  7.1.2. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market
7.2. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.2.1. U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.2.2. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.2.3. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.2.4. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.2.5. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.2.6. Rest of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market
7.3. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.3.1. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.3.2. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.3.3. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.3.4. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.3.5. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.3.6. Rest of Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market
7.4. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.4.1. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.4.2. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.4.3. Rest of Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market
7.5. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.5.1. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.5.2. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market
  7.5.3. Rest of Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

8.1. Key Company SWOT Analysis
  8.1.1. Company
  8.1.2. Company
  8.1.3. Company
8.2. Top Market Strategies
8.3. Company Profiles
  8.3.1. Alkem Laboratories Ltd.
    8.3.1.1. Key Information
    8.3.1.2. Overview
    8.3.1.3. Financial (Subject to Data Availability)
    8.3.1.4. Product Summary
    8.3.1.5. Market Strategies
  8.3.2. Apotex Inc.
  8.3.3. Aquestive Therapeutics Inc.
  8.3.4. Brainstorm Cell Therapeutics Inc.
  8.3.5. CORESTEM Inc.
  8.3.6. Dr Reddys Laboratories Ltd.
  8.3.7. Eledon Pharmaceuticals Inc.
  8.3.8. Ionis Pharmaceuticals Inc.
  8.3.9. Italfarmaco Holding SPA
  8.3.10. Medindia Health
  8.3.11. Mitsubishi Chemical Group Corp.
  8.3.12. Otsuka Holdings Co. Ltd.
  8.3.13. AB Science SA
  8.3.14. Biogen Inc.
  8.3.15. Cytokinetics Inc

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process
  9.1.1. Data Mining
  9.1.2. Analysis
  9.1.3. Market Estimation
  9.1.4. Validation
  9.1.5. Publishing
9.2. Research Attributes

LIST OF TABLES

TABLE 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market, report scope
TABLE 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market estimates & forecasts by Region 2022-2032 (USD Million)
TABLE 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market estimates & forecasts by Type 2022-2032 (USD Million)
TABLE 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market estimates & forecasts by Distribution Channel 2022-2032 (USD Million)
TABLE 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 9. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 11. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 15. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment market estimates & forecasts, 2022-2032 (USD Million)
TABLE 16. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 17. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 18. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment market estimates & forecasts, 2022-2032 (USD Million)
TABLE 19. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 20. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment market estimates & forecasts by segment 2022-2032 (USD Million)
…..
This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.

LIST OF FIGURES

FIG 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market, research methodology
FIG 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market, market estimation techniques
FIG 3. Global market size estimates & forecast methods.
FIG 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market, key trends 2023
FIG 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market, growth prospects 2022-2032
FIG 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market, porters 5 force model
FIG 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market, PESTEL analysis
FIG 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market, value chain analysis
FIG 9. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by segment, 2022 & 2032 (USD Million)
FIG 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by segment, 2022 & 2032 (USD Million)
FIG 11. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by segment, 2022 & 2032 (USD Million)
FIG 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by segment, 2022 & 2032 (USD Million)
FIG 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market by segment, 2022 & 2032 (USD Million)
FIG 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market, regional snapshot 2022 & 2032
FIG 15. North America Amyotrophic Lateral Sclerosis (ALS) Treatment market 2022 & 2032 (USD Million)
FIG 16. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment market 2022 & 2032 (USD Million)
FIG 17. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment market 2022 & 2032 (USD Million)
FIG 18. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment market 2022 & 2032 (USD Million)
FIG 19. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment market 2022 & 2032 (USD Million)
FIG 20. Global Amyotrophic Lateral Sclerosis (ALS) Treatment market, company market share analysis (2023)
…..
This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.


More Publications